Geode Capital Management
LXRX icon

Geode Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Geode Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
6,244,372
+3,075,261
+97% +$5.99M ﹤0.01% 2316
2026
Q1 		$4.95M Buy
3,169,111
+669,089
+27% +$973K ﹤0.01% 2741
2025
Q4 		$2.88M Buy
2,500,022
+102,099
+4% +$140K ﹤0.01% 3032
2025
Q3 		$3.24M Buy
2,397,923
+20,229
+0.9% +$23K ﹤0.01% 3000
2025
Q2 		$2.25M Sell
2,377,694
-1,311,577
-36% -$850K ﹤0.01% 3105
2025
Q1 		$1.7M Buy
3,689,271
+168,016
+5% +$106K ﹤0.01% 3104
2024
Q4 		$2.6M Sell
3,521,255
-2,716
-0.1% -$3.27K ﹤0.01% 3037
2024
Q3 		$5.53M Buy
3,523,971
+273,436
+8% +$487K ﹤0.01% 2707
2024
Q2 		$5.46M Buy
3,250,535
+861,398
+36% +$1.55M ﹤0.01% 2675
2024
Q1 		$5.73M Buy
2,389,137
+40,221
+2% +$86.4K ﹤0.01% 2624
2023
Q4 		$3.59M Buy
2,348,916
+222,779
+10% +$265K ﹤0.01% 2863
2023
Q3 		$2.32M Buy
2,126,137
+285,700
+16% +$501K ﹤0.01% 3025
2023
Q2 		$4.21M Buy
1,840,437
+115,028
+7% +$305K ﹤0.01% 2781
2023
Q1 		$4.19M Buy
1,725,409
+117,468
+7% +$269K ﹤0.01% 2718
2022
Q4 		$3.07M Buy
1,607,941
+38,919
+2% +$82.8K ﹤0.01% 2892
2022
Q3 		$3.77M Buy
1,569,022
+227,609
+17% +$630K ﹤0.01% 2821
2022
Q2 		$2.5M Buy
1,341,413
+83,549
+7% +$159K ﹤0.01% 3037
2022
Q1 		$2.63M Buy
1,257,864
+60,125
+5% +$167K ﹤0.01% 3115
2021
Q4 		$4.72M Buy
1,197,739
+3,817
+0.3% +$18.5K ﹤0.01% 2927
2021
Q3 		$5.74M Sell
1,193,922
-86,732
-7% -$356K ﹤0.01% 2831
2021
Q2 		$5.88M Buy
1,280,654
+202,496
+19% +$975K ﹤0.01% 2807
2021
Q1 		$6.33M Buy
1,078,158
+308,570
+40% +$2.14M ﹤0.01% 2668
2020
Q4 		$2.63M Sell
769,588
-5,369
-0.7% -$10.2K ﹤0.01% 2929
2020
Q3 		$1.11M Sell
774,957
-43,918
-5% -$78.2K ﹤0.01% 3168
2020
Q2 		$1.63M Buy
818,875
+132,573
+19% +$260K ﹤0.01% 2950
2020
Q1 		$1.34M Buy
686,302
+16,165
+2% +$48.1K ﹤0.01% 2889
2019
Q4 		$2.78M Sell
670,137
-1,433
-0.2% -$5.52K ﹤0.01% 2796
2019
Q3 		$2.02M Buy
671,570
+18,588
+3% +$57.5K ﹤0.01% 2936
2019
Q2 		$4.11M Buy
652,982
+29,862
+5% +$179K ﹤0.01% 2516
2019
Q1 		$3.46M Buy
623,120
+58,035
+10% +$353K ﹤0.01% 2538
2018
Q4 		$3.75M Buy
565,085
+13,664
+2% +$111K ﹤0.01% 2398
2018
Q3 		$5.88M Buy
551,421
+23,251
+4% +$266K ﹤0.01% 2248
2018
Q2 		$6.34M Buy
528,170
+76,428
+17% +$782K ﹤0.01% 2177
2018
Q1 		$3.87M Buy
451,742
+7,923
+2% +$73.3K ﹤0.01% 2403
2017
Q4 		$4.38M Buy
443,819
+11,169
+3% +$116K ﹤0.01% 2283
2017
Q3 		$5.32M Buy
432,650
+9,828
+2% +$145K ﹤0.01% 2172
2017
Q2 		$6.96M Sell
422,822
-10,598
-2% -$164K ﹤0.01% 1909
2017
Q1 		$6.21M Buy
433,420
+4,141
+1% +$61.4K ﹤0.01% 1957
2016
Q4 		$5.94M Buy
429,279
+20,482
+5% +$329K ﹤0.01% 1951
2016
Q3 		$7.39M Sell
408,797
-7,560
-2% -$122K ﹤0.01% 1694
2016
Q2 		$5.97M Buy
416,357
+63,165
+18% +$857K ﹤0.01% 1793
2016
Q1 		$4.22K Buy
353,192
+33,598
+11% +$352K ﹤0.01% 1973
2015
Q4 		$4.25M Buy
319,594
+16,829
+6% +$207K ﹤0.01% 1983
2015
Q3 		$3.25M Buy
302,765
+2,615
+0.9% +$28.6K ﹤0.01% 2128
2015
Q2 		$2.42M Buy
300,150
+31,030
+12% +$228K ﹤0.01% 2378
2015
Q1 		$1.78M Buy
269,120
+9,529
+4% +$65.1K ﹤0.01% 2517
2014
Q4 		$1.65M Buy
259,591
+9,021
+4% +$72.7K ﹤0.01% 2541
2014
Q3 		$2.47M Buy
250,570
+4,514
+2% +$48.2K ﹤0.01% 2234
2014
Q2 		$2.77M Buy
246,056
+37
+0% +$397 ﹤0.01% 2178
2014
Q1 		$2.98M Buy
246,019
+7,314
+3% +$93.5K ﹤0.01% 2102
2013
Q4 		$3.01M Buy
238,705
+2,450
+1% +$39K ﹤0.01% 2057
2013
Q3 		$3.92M Sell
236,255
-62,213
-21% -$1.04M ﹤0.01% 1740
2013
Q2 		$4.53M Buy
+298,468
New +$4.54M ﹤0.01% 1488

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management's LXRX Position: Q2 2026 in Review

Geode Capital Management increased its Lexicon Pharmaceuticals (LXRX) stake by 97% in Q2 2026, buying an estimated $5.99M and bringing the position to 6,244,372 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

Geode Capital Management first reported a position in LXRX in Q2 2013 and has held it in 53 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Geode Capital Management held 6,244,372 shares of Lexicon Pharmaceuticals worth $15M as of Q2 2026.
  • Geode Capital Management bought 3,075,261 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $5.99M.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2316 holding.
  • Geode Capital Management first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.